Preparation, characterization, and in vitro/vivo evaluation of polymer-assisting formulation of Atorvastatin calcium (cas 134523-03-8) based on solid dispersion technique

Add time:07/30/2019    Source:sciencedirect.com

Due to low solubility and bioavailability, Atorvastatin calcium (cas 134523-03-8) is confronted with challenge in conceiving appropriate formulation. Solid dispersion of atorvastatin calcium was prepared through the solvent evaporation method, with Poloxamer 188 as hydrophilic carriers. This formulation was then characterized by scanning electron microscopy, differential scanning calorimetry, powder X-ray diffraction and fourier transform infrared spectroscopy. Moreover, all these studies suggested the conversion of crystalline atorvastatin calcium. In addition, the drug solubility studies as well as dissolution rates compared with bulk drug and market tablets Lipitor were also examined. Furthermore, the study investigated the pharmacokinetics after oral administration of Lipitor and solid dispersion. And the AUC0–8 h and Cmax increased after taking ATC-P188 solid dispersion orally compared with that of Lipitor. All these could be demonstrated that ATC-P188 solid dispersions would be prospective means for enhancing higher oral bioavailability of ATC.

We also recommend Trading Suppliers and Manufacturers of Atorvastatin calcium (cas 134523-03-8). Pls Click Website Link as below: cas 134523-03-8 suppliers

Prev:Preparation of a carboxymethylcellulose-iron composite for uptake of Atorvastatin (cas 134523-00-5) in water
Next:The studies of PLGA nanoparticles loading Atorvastatin calcium (cas 134523-03-8) for oral administration in vitro and in vivo)